Nearly two-thirds of plan sponsors say the economy is causing a shift toward placing greater accountability on members to manage their own health so plan dollars are spent more wisely
Plan sponsors are rethinking the pharmacy benefit in light of the financial crisis, according to Medco Health Solutions Inc.
According to the 9 Leading Trends in Rx Plan Management, a report based on a nationwide survey of plan sponsors conducted for Medco’s Systemed Group by Haldy McIntosh and Associates, nearly two-thirds of plan sponsors say the economy is causing a shift toward placing greater accountability on members to manage their own health so plan dollars are spent more wisely.
“Across a number of questions, this year’s report indicates a substantial willingness to seek more innovative solutions in order to achieve these goals-from shifting member cost share to embracing innovation and technology,” says Nancy Wybolt, senior manager, marketing, Medco.
The findings in the 9 Trends report reflect the perceptions of 300 pharmacy benefit managers from leading corporations, as well as nonprofit, labor and public sector groups with between 500 and 50,000+ employees.
According to Wybolt, the biggest surprise was in the similarity of responses among a variety payer audiences-employers between 500 and 50,000+, private and public sectors, as well as labor unions-are focused on similar issues and management tools.
“A few examples are genetic testing as a routine part of healthcare, mail-order pharmacy as a means identify gaps in care and drive better adherence to essential drug therapies and the need for an FDA approved bio-similar pathway,” Wybolt says. “This alignment highlights everyone’s desire to provide quality care, but remove waste and cost from the system.”
Wybolt says 80% of organizations surveyed intend to integrate their drug and medical data to help improve health and financial outcomes.
FDA Site Inspections Decreased During Pandemic. Questions Continue about Drug Quality.
December 4th 2023A recent study has found that FDA inspections of drug manufacturing facilities have increased since the COVID-19 health emergency but have not yet returned to pre-pandemic numbers.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
RSV Vaccines for Adults: Gaps in Understanding
December 4th 2023Angela Branche, M.D., an infectious disease specialist at the University of Rochester School of Medicine, says the gaps are in a precise understanding of who is at risk for serious illness from respiratory syncytial virus and therefore who should get vaccinated.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen